AC Immune (ACIU) Income from Continuing Operations (2015 - 2026)

AC Immune (ACIU) has 12 years of Income from Continuing Operations data on file, last reported at 18900946.3 in Q1 2026.

• On a quarterly basis, Income from Continuing Operations rose 10.7% year-over-year to 18900946.3 in Q1 2026; TTM through Mar 2026 was 82302232.45, a 41.87% decrease from a year earlier, with the FY2025 full-year figure at 84968134.06, down 46.21% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 18900946.3, down from 17983063.42 in the prior quarter.
• Over the last five years, Income from Continuing Operations for ACIU reached as high as 6351602.46 in Q3 2024 and fell as low as 25593986.06 in Q2 2025.
• Historically, Income from Continuing Operations has averaged 17360965.7 across 5 years, with a median of 18927913.25 in 2023.
• Across the five-year window, Income from Continuing Operations jumped 137.06% in 2024 and sank 412.11% in 2025, its largest moves.
• Year by year, Income from Continuing Operations stood at 19457720.74 in 2022, then soared by 72.53% to 5345914.91 in 2023, then slumped by 237.25% to 18029196.07 in 2024, then gained by 0.26% to 17983063.42 in 2025, then retreated by 5.1% to 18900946.3 in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 18900946.3 in Q1 2026, 17983063.42 in Q4 2025, and 19824236.68 in Q3 2025.